Breaking News

Bioclinica Launches Post-Approval Research Division

January 28, 2016

Aims to streamline overall study resource requirements

Bioclinica has launched a new Post-Approval Research division as part of its Global Clinical Research business segment. Leveraging its technology expertise, the service aims to streamline overall study resource requirements, and is flexible, scalable and customizable. It offers full access to real-time study metrics and transparency for all stakeholders.
The Post-Approval Research operates a Program Coordinating Center (PCC) with dedicated research staff and provides global operational infrastructure from centralized locations to support local languages and time differences. Also, the Patient Outreach Center (POC) offers processes and technology designed to increase patient compliance and data collection by 25-30%, compared to traditional methodologies and Patient-Reported Outcomes, according to the company.
"At Bioclinica, we understand the fundamental differences between the design and conduct of post-approval studies and those performed prior to approval. We believe the substantial and deep domain knowledge of our management team, coupled with our state-of the-art-technology, allows us to achieve our strategic goals in post-approval research," said Dr. John Hubbard, president and chief executive officer, Bioclinica
  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus

  • Robust Assay Designs

    Robust Assay Designs

    Tim Wright, Editor, Contract Pharma||October 11, 2016
    Easing the transition from preclinical to clinical research